Please enable JS

Manufacturing

Our strategy is to become a fully integrated biopharmaceutical company in China.

In addition to assembling an experienced internal research and development team, we have already built a cGMP-compliant small molecule facility capable of supporting clinical and commercial production and have begun construction of a cGMP-compliant large molecule facility capable of supporting clinical production of our drug candidates in China.

The construction of the large molecule facility is expected to be completed in the first half of 2018.